Gracell Biotechnologies Inc.
Gracell Biotechnologies Inc. (GRCL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GRCL · as of Dec 31, 2023
Ownership Breakdown
69
Institutional Holders
▲ 26 vs Q3
$552.02M
Total Inst. Value
▲ $417.76M vs Q3
3.86M
Shares Outstanding
freeFloat 85.45%
55.16M
13F Shares Held
▲ 6.75M vs Q3
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GRCL largest shareholders · institutional ownership
Q4 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TEMASEK HOLDINGS (PRIVATE) LTD pharmaceutical preparations | 9.59M | 11.43% | 11.43% | $96.27B | Feb 14, 2024 | ▼ 313.1K |
VIVO CAPITAL, LLC pharmaceutical preparations | 9.55M | 11.38% | 11.38% | $95.85B | Feb 7, 2024 | ▼ 1.33M |
ORBIMED ADVISORS LLC pharmaceutical preparations | 9.31M | 11.09% | 11.09% | $93.46B | Feb 14, 2024 | — held |
SIO CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.00M | 5.96% | 5.96% | $50.22B | Feb 13, 2024 | ▲ 2.92M |
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 4.51M | 5.38% | 5.38% | $45.33B | Feb 14, 2024 | ▲ 1.48M |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.19M | 2.61% | 2.61% | $22.00B | Feb 14, 2024 | ▲ 2.03M |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 2.08M | 2.48% | 2.48% | $20.88B | Feb 14, 2024 | ▲ 1.08M |
PENTWATER CAPITAL MANAGEMENT LP pharmaceutical preparations | 1.46M | 1.74% | 1.74% | $14.67B | Feb 14, 2024 | NEW |
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC pharmaceutical preparations | 1.38M | 1.64% | 1.64% | $13.80B | Feb 13, 2024 | — held |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 1.35M | 1.61% | 1.61% | $13.55B | Feb 14, 2024 | ▲ 500.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q4 2023 vs prior quarter
Q4 2023
14
Increased
+9.57M shares25
New Positions
first time holders8
Decreased
−4.46M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.11M
+9.57M / −4.46M
Net new holders
+31
25 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GRCL insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Gracell Biotechnologies Inc. (GRCL) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 14.55%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Gracell Biotechnologies Inc. is TEMASEK HOLDINGS (PRIVATE) LTD, holding approximately 9.59 million shares — equal to 11.43% of outstanding shares — as of December 31, 2023.
A total of 69 institutional investors currently hold GRCL stock, with a combined institutional value of approximately $552,021,995 as of the most recent 13F filing period.
Frequently asked questions
GRCL ownershipGracell Biotechnologies Inc. (GRCL) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is TEMASEK HOLDINGS (PRIVATE) LTD with a 11.43% stake. Company insiders hold 14.55%. Data sourced from SEC Form 13F as of December 31, 2023.